Arcellx Aktie News

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that a late-breaking abstract for its novel D-Domain binder in anitocabtagene autoleucel (anito-cel) has been accepted for presentation at the 2026 Tandem Meetings. BCMA...

David Charles Lubner, a director at Arcellx, exercised 6,000 shares, which were sold immediately on Jan. 20, 2026, resulting in a transaction value of approximately $450,000. This disposition represented 21.69% of Lubner's direct holdings, and holds over 21,000 shares post-transaction.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, is advancing both its scientific foundation for its D-Domain platform technology and commercial preparedness for anito-cel for the potential treatment of multiple myeloma...

Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, and scalable manufacturing. ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, 74% CR/sCR, and clean safety profile differentiate it from competitors, especia...

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.

Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple mye...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will host an Investor Relations event on Saturday, December 6, 2025 at 8:00 p.m. ET. The event will include a panel of clinician experts a...